OQS
PRLD icon

Occudo Quantitative Strategies’s Prelude Therapeutics PRLD Stock Holding History

Occudo Quantitative Strategies’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,640
Closed -$123K – 1370
2022
Q2 		$123K Sell
23,640
-598
-2% -$3.04K 0.01% 994
2022
Q1 		$167K Buy
24,238
+2,845
+13% +$26K 0.01% 971
2021
Q4 		$266K Buy
+21,393
New +$348K 0.02% 805

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Occudo Quantitative Strategies's PRLD Position: Q3 2022 in Review

Occudo Quantitative Strategies sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 23,640 shares — an estimated $123K sold.

Occudo Quantitative Strategies first reported a position in PRLD in Q4 2021 and held it in 3 quarters. The position peaked at $266K in Q4 2021. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

  • Occudo Quantitative Strategies reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 23,640 Prelude Therapeutics shares in Q3 2022, an estimated $123K.
  • Occudo Quantitative Strategies first reported a position in Prelude Therapeutics in Q4 2021 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Prelude Therapeutics position peaked at $266K in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.